Abstract
Free immunoglobulin E (IgE) concentration is a key biomarker for allergic diseases. Prediction of free IgE concentration can help clinicians diagnose and monitor allergic diseases more effectively. In this study, we used machine learning to predict free IgE concentration in the blood serum of patients with allergic rhinitis who received allergen immunotherapy co-administered with omalizumab. The predictors for free IgE concentration were the number of visits for treatment and baseline checking, and treatment groups (1) omalizumab/ragweed, (2) omalizumab/placebo, (3) placebo/ragweed, and (4) placebo/placebo. Several machine learning algorithms (MLA) were trained with the immunotherapy dataset imported from Immune Tolerance Network (ITN) TrialShare into the Orange data mining platform. The decision tree algorithm model amidst the list of MLAs trained and tested was the best performing model for predicting free IgE concentration, with an R-squared of about 0.6. This study demonstrates that machine learning can be used to predict free IgE concentration with high accuracy. This prediction model could be used to help clinicians diagnose and monitor allergic diseases more effectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Office of Sponsor program at Prairie View A & M University, TX 77446
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source of the dataset is Immune Tolerance Network/TrialShare. I registered with my username and password and I was given access to the Dataset. It is in the NIH-Supported Data Sharing Resources (https://www.nlm.nih.gov/NIHbmic/domain_specific_repositories.html). This is the link to the ITN/TrialShare (https://www.immunetolerance.org/researchers/trialshare).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to update the Corresponding Author's name by including his initial B.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
